Melphalan/HDS

COMBINATION_PRODUCT3 trials

Sponsors

Delcath Systems Inc.

Conditions

Bile Duct CancerHepatocellular Carcinoma (HCC)Intrahepatic CholangiocarcinomaOcular MelanomaUveal Melanoma

Phase 2

Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC

WithdrawnNCT02406508

Delcath Systems Inc.Hepatocellular Carcinoma (HCC)

Start: 2014-10-31End: 2017-12-31Updated: 2017-12-18

Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma

Delcath Systems Inc.Bile Duct Cancer, Intrahepatic Cholangiocarcinoma

Start: 2018-04-10End: 2023-05-31Target: 295Updated: 2022-03-24

Phase 3

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

CompletedNCT02678572

Delcath Systems Inc.Ocular Melanoma, Uveal Melanoma

Start: 2016-02-01End: 2023-08-15Updated: 2026-09-10

Related Papers

Melphalan/hepatic delivery system versus best available care in patients with unresectable metastatic uveal melanoma: Randomized FOCUS trial results.

Journal of Clinical Oncology2024-06-01

Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.

2024-05-0421 citations

FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A).

Journal of Clinical Oncology2022-06-0145 citations

Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases: Preliminary results of FOCUS (PHP-OCM-301/301A) phase III trial.

Journal of Clinical Oncology2021-05-2012 citations